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Selective lymphocyte inhibition by FTY720 slows the progres-
sive course of chronic anti-thy 1 glomerulosclerosis.
Background. Progression is a hallmark of chronic renal dis-
ease and histologically characterized by fibrosis and inflamma-
tion of the tubulointerstitial compartment. To define the role of
lymphocytes in this process, the novel lymphocyte-specific in-
hibitor FTY720 was administered to rats with anti-thy 1-induced
chronic progressive glomerulosclerosis. In this model, the initial
and short-term inflammatory glomerular injury progresses self-
perpetuatedly toward tubulointerstitial fibrosis by not primarily
immune-mediated, intrarenal mechanisms.
Methods. Chronic progressive glomerulosclerosis was in-
duced by murine anti-thy 1 antibody injection into uninephrec-
tomized rats. Treatment with FTY720 (0.3 mg/kg body weight)
was started 7 days after disease induction. Proteinuria was mea-
sured every 4 weeks. In week 20, the following parameters
were determined: blood lymphocyte number, kidney function,
both glomerular and tubulointerstitial histologic matrix accu-
mulation, protein expression of transforming growth factor-b1
(TGF-b1), fibronectin, and plasminogen activator inhibitor-1
(PAI-1) as well as infiltration with macrophages and lympho-
cytes.
Results. Treatment with FTY720 lowered blood lymphocyte
count and renal lymphocyte infiltration highly significantly. In
comparison to the untreated chronic progressive glomeruloscle-
rosis animals, the lymphocyte depletion achieved significantly
limited the progression of the disease, as shown by lowered
proteinuria, tubulointerstitial matrix expansion, and TGF-b1,
fibronectin, and PAI-1 expression, as well as improved re-
nal function. Glomerular matrix protein expression and ac-
cumulation was moderately lowered by FTY720. Glomerular
macrophage infiltration was not, tubulointerstitial macrophage
infiltration was moderately, but not significantly, decreased by
FTY720 treatment.
Conclusion. Lymphocyte depletion by FTY720 limits the
progression of anti-thy 1–induced glomerulosclerosis toward
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chronic tubulointerstitial fibrosis and renal insufficiency. The
data suggest that lymphocytes actively participate in the pro-
gression of chronic experimental kidney disease, and that
FTY720 may be a novel approach to slow the progressive course
of human chronic renal diseases.
Chronic kidney diseases are uniformly characterized
by a progressive loss of organ function leading ultimately
to end-stage renal disease and the need for dialysis or
transplantation [1, 2]. Disease progression is seen inde-
pendently, whether the underlying disorder is diabetes,
hypertension, or glomerulonephritis. Since ongoing dete-
rioration of renal function can be observed even when the
initial disease has been resolved, it is assumed that a ma-
jor part of the progression is driven by self-perpetuated,
intrarenal mechanisms, after a certain point of no return
has been passed [1]. Similar to kidney disorders, a uni-
form progressive loss of organ function is also seen in
chronic diseases of the heart, circulation, liver, lungs, and
brain [3–8], suggesting that a common final pathway is
underlying progressive organ destruction and failure.
As early as in 1931, Addis and Oliver [9] recognized
that an “inflammatory scarring” of the tubulointerstitial
compartment is a hallmark of chronic renal diseases. Sub-
sequently, others have shown that tubulointerstitial injury
and fibrosis correlate best with renal disease progression
and insufficiency and develop independently, no matter
whether they originate from primarily glomerular or vas-
cular lesions [10–12]. The term “inflammatory scarring”
elegantly condenses the close temporal and spatial inter-
action of the two key components of progressive renal
disease: inflammation and fibrosis. With regard to tis-
sue fibrosis, overproduction of the cytokine transform-
ing growth factor-b (TGF-b) has been identified as key
mediator of tissue matrix accumulation in the last decade
[13]. Expression of TGF-b uniformly increases to various
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kinds of tissue injury and uniquely facilitates tissue fi-
brosis via an increase in the production of matrix pro-
teins such as fibronectin, biglycan, and collagens, a
decrease of matrix protein degradation by increased pro-
duction of protease inhibitors such as plasminogen activa-
tor inhibitor-1 (PAI-1), and an overexpression of matrix-
binding integrins on the cell surface [13]. With regard
to tissue inflammation in chronic kidney disorders, a
prominent round cell infiltration in the tubulointerstitium
characterizes both human and experimental disease and
consists mainly of macrophages and lymphocytes [14, 15].
Recent research has shown that macrophages, represent-
ing primarily the unspecific immune response, play an
active role in the pathogenesis of chronic renal disease
[16]. This contrasts to the role of lymphocytes, which has
not received large attention yet. Since lymphocytes rep-
resent the adaptive and specific immune system, and in
view of the rather unspecific nature of cell inflammation
in chronic renal disease, they have generally been consid-
ered “innocent bystanders” [14, 15].
The present study was designed to test the hypoth-
esis that lymphocytes participate actively in the pro-
gressive course of chronic renal disease. To test this
hypothesis, rats with anti-thy 1–induced chronic pro-
gressive glomerulosclerosis were treated with the novel
lymphocyte-specific immunosuppressant FTY720. Anti-
thy 1–induced chronic glomerulosclerosis is produced
immunologically by injection of anti-thy 1 antibodies
into uninephrectomized rats, leading to a short-term
complement- and nitric oxide–mediated acute glomeru-
lonephritis [17, 18]. Afterwards, the disease progresses
autonomously toward glomerulosclerosis, tubulointersti-
tial fibrosis, and renal insufficiency over months in a not
primarily immune-mediated manner. The kind of pro-
gression in anti-thy 1–induced chronic glomerulosclero-
sis contrasts to the one seen in diabetic and hypertensive
nephropathy, in which ongoing and extrarenal injuri-
ous stimuli are additionally driving the disease. In this
sense, the model of chronic anti-thy 1 glomerulosclerosis
provides a unique opportunity to analyze the mecha-
nisms underlying intrarenal “pure” progression. FTY720,
2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, was
selected because it makes it possible to study the long-
term role of lymphocytes in various disease states specif-
ically [19, 20]. Although the molecular mechanisms
are still incompletely understood, FTY720 selectively
elicits marked lymphopenia by reversibly sequestrating
lymphocytes into secondary lymphatic organs [19, 20].
Treatment with FTY720 was started 1 week after injec-
tion of the anti-thy 1 antibody (i.e., when the glomerular
disease already had been established). Proteinuria was
analyzed every month, and, in week 20 after disease in-
duction, the actions of FYT720 on blood and renal white
cell numbers, glomerular and tubulointerstitial fibrosis,
and renal function were determined.
METHODS
Materials
Unless otherwise indicated, materials, chemicals, or
culture media were purchased from Sigma-Aldrich
Chemicals Co. (Taufkirchen, Germany).
Animals
Male Wistar rats (130 to 150 g) obtained from Charles
River (Sulzfeld, Germany) were fed a normal protein diet
(22.5% protein, A1311) (Altromin, Lage, Germany) for
at least 3 days before the start of the experiment to allow
equilibration. Animal care and treatment were in confor-
mity with the guidelines of the American Physiological
Society and approved by local authorities. Animals were
housed in a constant temperature room with a 12-hour
dark/12-hour light cycle. Body weight was determined
weekly. Food intake was monitored daily.
Model of anti-thy 1–induced chronic progressive
glomerulosclerosis
Chronic progressive glomerulosclerosis was induced
by surgically removing one kidney and intravenously in-
jecting the monoclonal antibody 1-22-3 [5 mg/kg body
weight in phosphate-buffered saline (PBS), pH = 7.4]
3 days later [17, 18]. The antibody 1-22-3 antibody binds
to a thy 1–like antigen on the surface of mesangial cells of
the kidney and causes a fast complement and nitric oxide-
dependent mesangial cell lysis within the next 24 hours
[17, 18]. Control animals with and without uninephrec-
tomy were injected with equal volumes of PBS
only.
Although induced by a brief immunologic glomeru-
lar insult, the progression in chronic anti-thy 1 glomeru-
losclerosis toward tubulointerstitial fibrosis over months
is not primarily immune-mediated. Disease progres-
sion in this model has been linked to the uninephrec-
tomy that is performed prior to anti-thy 1 antibody
injection, since in animals with two kidneys the glomeru-
lar disease resolves over approximately 4 weeks [17, 21].
Furthermore, treatment with FTY720 was started 7 days
after disease induction to avoid interference with the im-
munologic insult by anti-thy antibody injection.
Production of monoclonal antibody 1-22-3
Monoclonal antibody 1-22-3 was produced from a hy-
bridoma cell line as previously described [17]. The an-
tibody was lyophilized, stored at −70◦C, and diluted in
PBS at a concentration of 2 mg/mL before use.
FTY720 treatment
FTY720 was kindly provided by Novartis Pharma
GmbH (Basel, Switzerland). The drug was given with
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the food in a dose of 0.3 mg/kg body weight. The dose
was chosen on the basis of previous reports showing
effective reduction in blood lymphocyte count in rat dis-
ease models [19]. The food containing FTY720 was pro-
duced in our laboratory by using the flour of the standard
rat chow (22.5% protein, A1311) (Altromin). The drug
was mixed into the dry food flour in appropriate amounts,
water was added to form pellets, and the air-dried pellets
were subsequently given to the FTY720-treated animals.
Experimental groups and design
A 24-hour urine was collected 1 week after anti-thy 1
antibody injection. On the basis of the actual 24-hour
proteinuria achieved, the nephritic animals were ran-
domly assigned to the untreated and treated chronic
progressive glomerulosclerosis groups. For the whole
experiment, the following groups were formed: (1) PBS-
injected normal rats, with two kidneys (N = 4) (two-
kidney control); (2) uninephrectomized, PBS-injected
controls (N = 4) (one-kidney control); (3) uninephrec-
tomized, anti-thy 1 antibody–injected animals, no treat-
ment (N = 9) (chronic progressive glomerulosclerosis);
and (4) uninephrectomized, anti-thy 1 antibody–injected
rats plus FTY720 (N = 9) (chronic progressive glomeru-
losclerosis + FTY720).
Twenty weeks after induction of chronic anti-thy 1
glomerulosclerosis, the effects of FTY720 on blood and
renal lymphocyte count were analyzed. In addition, both
glomerular and tubulointerstitial matrix accumulation
were determined by scoring matrix expansion histolog-
ically and measuring the glomerular and cortical protein
expression of TGF-b1, fibronectin, and PAI-1. TGF-b1
is a key marker and mediator of renal fibrosis, fibronectin
is an indicator for matrix protein production, and the
protease inhibitor PAI-1 was used as sensitive marker
of the matrix degrading system [13, 22]. TGF-b1, fi-
bronectin, and PAI-1 expression were measured at the
protein level in the supernatant of cultured glomeruli
or minced cortical tissue harvested from individual
animals [18] and by immunohistochemical staining. To
document that renal fibrosis closely correlates with renal
insufficiency, plasma creatinine and blood urea nitrogen
(BUN) were measured as plasma markers of excretory
renal function. In addition, the blood erythrocytes count
was analyzed as a marker for renal endocrine erythro-
poetin production, indicating more advanced functional
impairment.
Measuring proteinuria, systolic blood pressure,
and heart rate
A 24-hour urine was collected from each rat 1, 4, 8,
12, 16, and 20 weeks after induction of chronic anti-thy 1
glomerulosclerosis, using metabolic cages. Urinary pro-
tein was measured by a pyrogallol red method using a
microplate technique [23]. Proteinuria is expressed as mg
protein/24 hours. Two days before the end of the exper-
iment, systolic blood pressure and hearth rate was mea-
sured in conscious animals by a tail-cuff method, as pre-
viously described [23].
Sacrifice
For sacrifice, the animals were anesthetized with ketan-
est (50 mg/kg body weight) (Pharmacia GmbH, Erlangen,
Germany)/xylazin (10 mg/kg body weight) (Bayer Vital
GmbH, Leverkusen, Germany). Following a midline ab-
dominal incision, 5 to 10 mL heparinized blood was drawn
from the abdominal aorta, and the kidneys were subse-
quently perfused with 30 mL ice-cold PBS. Materials and
tissues were subsequently processed as described in the
following sections.
Blood analysis
Blood cell populations and counts were analyzed in
an automated cell counter (XE 2100) (Sysmex GmbH,
Norderstedt, Germany) using a standard fluorescent
flow cytometry technology [24]. Blood lymphocyte sub-
populations were analyzed using a FACSCalibur as
cell sorter (BD Biosciences, Heidelberg, Germany) and
fluorochrome-conjugated antirat CD3, CD4, and CD8
antibodies as previously described (BD Biosciences) [25].
Plasma and urine creatinine and plasma BUN concentra-
tions were measured spectrophotometrically in enzyme-
based assays [18].
Histology
For histologic examination, cortical tissue was fixed
in 10% neutral buffered formalin or snap-frozen in liq-
uid nitrogen. All microscopic examinations were per-
formed in a blinded fashion. For analyses of glomerular
and tubulointerstitial matrix accumulation, 3 lm sections
of paraffin-embedded tissue were stained with periodic
acid-Schiff (PAS). Glomerular matrix expansion was
evaluated by rating the mesangial matrix-occupying area
of 20 glomeruli from each rat, using the following scoring
system: 0, 0%; 1, 1% to 25%; 2, 26% to 50%; 3, 51% to
75%; and 4, 76% to 100% [18]. Tubulointerstitial matrix
deposition was assayed in 15 randomly selected cortical
areas per sample observed at ×200 magnification, using
the following scale: 0, normal; 1, lesions involving less
than 10% of cortical area; 2, involving 10% to 30%; 3,
involving 31% to 50%; and 4, involving more than 50%,
respectively [18].
Glomerular and tubulointerstitial TGF-b1, fibronec-
tin, and PAI-1 expression was analyzed immunohistologi-
cally. TGF-b staining was performed using formalin-fixed
paraffin sections and a primary rabbit antirat TGF-b1
antibody (Santa Cruz Biotechnology, Santa Cruz, CA,
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USA), the fibronectin staining with a primary rab-
bit anti-human fibronectin antibody (DakoCytomation,
Hamburg, Germany), respectively. For both, a secondary
goat antirabbit antibody was coupled with the Envi-
sionTM staining system (DakoCytomation). PAI-1 stain-
ing was done on acetone-fixed cryostat sections using
a primary rabbit antirat PAI-1 IgG fraction (Oxford
Biomedical Research, Oxford, MI, USA) and a fluores-
cein isothiocyanate (FITC) isomer 1–conjugated poly-
clonal swine antirabbit immunoglobulin (DakoCytoma-
tion) as secondary antibody. Matrix protein expression
was scored semiquantitatively for the glomerular and
tubulointerstitial compartment using a 4-grade scale as
previously described [26], with minor modifications: 0,
absent; 1, mild; 2, moderate; 3, marked; and 4, severe
staining intensity.
For analysis of cell infiltration, renal tissue was im-
munohistologically stained for CD4–positive and CD8–
positive (lymphocytes) and ED1–positive (macrophages)
cells. Paraffin-embedded tissues were incubated with a
primary mouse anti-CD8 and mouse anti-ED1 antibody,
cryoconserved material with a primary mouse anti-CD4
antibody, respectively (all from Serotec, Oxford, UK).
Further staining was performed using a standard APAAP
technique (DakoCytomation), as previously described
[27]. Glomerular cell infiltration was counted in at least 20
glomerular sections from each rat, tubulointerstitial cell
infiltration in at least 15 randomly selected cortical areas
per sample observed at ×200 magnification, respectively.
Production of TGF-b1, fibronectin, and PAI-1 by cortical
tissue or glomeruli in culture
Glomeruli from individual rats were isolated by a
graded sieving technique (160, 125, and 71 lm mesh metal
sieves), as described previously [22]. For cultures of renal
cortical tissue, a piece of cortical tissue was weighed and
minced extensively with a razor blade [18]. Glomeruli
or cortical tissue were suspended in Dulbecco’s mod-
ified Eagle’s medium (DMEM) supplemented with 0.1
U/mL insulin, 100 U/mL penicillin, and 100 lg/mL strep-
tomycin. Glomeruli were cultured at a density of 2000
glomeruli/mL for 48 hours, minced cortical tissue at a
density of 10 mg/mL, respectively. After 48 hours’ incu-
bation at 37◦C/5% CO2, supernatants were harvested and
stored at −70◦C until analysis of TGF-b1, fibronectin, or
PAI-1 content.
Measuring TGF-b1, fibronectin, and PAI-1
TGF-b1 content of culture supernatant was measured
after acid activation, using a commercially available
enzyme-linked immunosorbent assay (ELISA) kit (TGF-
b1 DuosetTM) (R&D Systems, Wiesbaden, Germany) ac-
cording to the manufacturer’s instructions. Fibronectin
and PAI-1 levels were measured with modified inhibitory
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Fig. 1. Effects of FTY720 on proteinuria in chronic progressive anti-thy
1 glomerulosclerosis (cGS). FTY720 treatment was started 7 days after
injection of anti-thy 1 antibody into uninephrectomized rats. Nondis-
eased animals with [one-kidney control (1-K control)] and without
uninephrectomy [two-kidney control (2-K control)] received an injec-
tion with similar volumes of phosphate-buffered saline (PBS). Urine
was collected for 24 hours at the indicated times, using metabolic cages.
∗P < 0.05 vs. chronic glomerulosclerosis.
ELISA, according to published methods [18]. Three sam-
ples from each rat were analyzed.
Statistical analysis
Data are expressed as mean ± standard error of the
mean (SEM). Statistical analysis between the groups was
performed by one-way analysis of variance (ANOVA)
and subsequent Mann-Whitney U testing. A P value <
0.05 was considered significant.
RESULTS
Body weight
At the end of the experiment, body weight had reached
562 ± 21 g in the normal (two-kidney control) and 564 ±
3 g in the uninephrectomized control group (one-kidney
control), respectively. In comparison, final body weight
was significantly lower in both nephritic groups (P < 0.05,
chronic progressive glomerulosclerosis 533 ± 12 g and
chronic progressive glomerulosclerosis + FTY720 519 ±
16 g, between both groups, P = 0.67), indicating chronic
renal disease and insufficiency. Food and water intakes
did not differ between the groups throughout the exper-
iment. The mean FTY720 doses actually achieved were
0.29 ± 0.01, 0.31 ± 0.06, and 0.27 ± 0.03 mg/kg body
weight in weeks 2, 10, and 20, respectively.
Effects of FTY720 on proteinuria, blood pressure,
and heart rate
As shown in Figure 1, pretreatment proteinuria was
markedly increased to a comparable degree 7 days after
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Fig. 2. Effects of FTY720 on the total blood white (A) and lymphocyte
cell counts (B) 20 weeks after induction of chronic anti-thy 1 glomeru-
losclerosis (cGS). FTY720 treatment was started 7 days after injection of
anti-thy 1 antibody into uninephrectomized rats. Nondiseased animals
without [two-kidney control (2-K control)] and with uninephrectomy
[one-kidney control (1-K control)] received a phosphate-buffered saline
(PBS) injection. Blood white cell analyses were performed by a stan-
dard automated fluorescent flow cytometry technology. ∗∗∗P < 0.001 vs.
chronic glomerulosclerosis.
induction of anti-thy 1 glomerulosclerosis in both
nephritic groups, indicating the efficacy of the randomiza-
tion procedure (chronic progressive glomerulosclerosis
98 ± 8 mg/day vs. chronic progressive glomerulosclero-
sis + FTY720 95 ± 8 mg/day, P = NS). In both groups,
a slight decrease in proteinuria was seen until week 8
after disease induction. Afterwards, proteinuria continu-
ously increased in the untreated chronic anti-thy 1 group,
indicating progression of disease, while in the FTY720-
treated animals, protein excretion remained relatively
stable over time. As a result, in week 20, proteinuria was
significantly lower in FTY720-treated animals than in the
untreated diseased controls (73 ± 19 mg/day vs. 171 ±
35 mg/day, P < 0.05).
In week 20, chronic-progressive anti-thy 1 glomeru-
losclerosis was characterized by a moderate increase in
systolic blood pressure (130 ± 3 mm Hg), as compared to
the nonnephritic control animals (two-kidney control 127
± 3 mm Hg and one-kidney control 125 ± 4 mm Hg). In
comparison to the disease control group, blood pressure
was slightly but not significantly lower in the FTY720-
treated diseased animals (125 ± 2 mm Hg). In addition,
heart rate was moderately lower in the FTY720-treated
group (chronic progressive glomerulosclerosis + FTY720
380 ± 8 bpm vs. chronic progressive glomerulosclerosis
396 ± 9 bpm, P = 0.30).
Effects of FTY720 on white blood cell count
Compared to the untreated chronic anti-thy 1 group,
administration of FTY720 resulted in a highly significant
reduction of the total white cell count by 71% (chronic
progressive glomerulosclerosis + FTY720 1.97 ± 0.14 ×
103 cells/lL vs. chronic progressive glomerulosclerosis
6.86 ± 0.46 × 103cells/lL, P < 0.001) (Fig. 2A), as shown
A B
DC
Fig. 3. Effects of FTY720 on the histologic picture 20 weeks after in-
duction of chronic anti-thy 1 glomerulosclerosis (cGS). FTY720 treat-
ment was started 7 days after injection of anti-thy 1 antibody into
uninephrectomized rats. Shown are characteristic periodic acid-Schiff
(PAS)-stained renal sections from (A) a nondiseased animal without
[two-kidney control (2-K control)] and (B) with uninephrectomy [one-
kidney control (1-K control)] and an animal with anti-thy 1–induced
chronic progressive renal fibrosis (C) without and (D) with FTY720
treatment (magnification ×200).
in the blood drawn 20 weeks after disease induction.
White blood cell differential analysis documented that
this decrease was mainly due to a 90% reduction in the
blood lymphocyte count (chronic progressive glomeru-
losclerosis + FTY720 0.47 ± 0.04 × 103 cells/lL vs.
chronic progressive glomerulosclerosis 4.92 ± 0.33 ×
103cells/lL, P < 0.001) (Fig. 2B). Further FACS analy-
sis showed that CD4–positive and CD8–positive blood
lymphocytes were equally decreased by FTY720 (data
not shown). The absolute number of blood neutrophils
and monocytes did not differ between the untreated and
FTY720-treated anti-thy 1 animals (data not shown).
These data confirm the in vivo bioavailability of FTY720
in this experiment and document its action as being pre-
dominantly directed toward lymphocytes.
Effects of FTY720 on renal matrix accumulation
The most prominent and important actions of FTY720
on renal matrix accumulation were observed in the tubu-
lointerstitial compartment. Characteristic photographs
are shown in Figure 3. Compared to the nondiseased con-
trol animals, progression of anti-thy 1 glomerulosclerosis
into the tubulointerstitial space was characterized by a
marked increase in the histologic tubulointerstitial ma-
trix score (1.88 ± 0.45) and the cortical protein expres-
sion of TGF-b1 (187 ± 16 pg/mL), fibronectin (1837 ±
228 ng/mL) (all P < 0.001 vs. two-kidney and one-kidney
control), and PAI-1 (64 ± 6 ng/mL) (P < 0.05 vs. two-
kidney and one-kidney control) (Fig. 4). Treatment with
FTY720 largely prevented the disease progression in
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Fig. 4. Effects of FTY720 on tubulointerstitial matrix accumulation
(A) and cortical production of transforming growth factor-b1 (TGF-b1)
(B), fibronectin (C), and plasminogen activator inhibitor (PAI-1) (D)
20 weeks after induction of chronic anti-thy 1 glomerulosclerosis (cGS).
FTY720 treatment was started 7 days after injection of anti-thy 1 anti-
body into uninephrectomized rats. Nondiseased animals without [two-
kidney control (2-K control)] and with uninephrectomy [one-kidney
control (1-K control)] received a phosphate-buffered saline (PBS) in-
jection. Matrix accumulation was scored histologically (grade 0 to 4).
Matrix protein production was determined in extensively minced indi-
vidual cortical tissues cultured at a density of 10 mg/mL for 48 hours.
∗P < 0.05 vs. chronic glomerulosclerosis.
chronic anti-thy 1 glomerulosclerosis, as documented by
markedly lowered histologic tubulointerstitial matrix ex-
pansion (matrix score 0.58 ± 0.15) and protein expres-
sion of TGF-b1 (136 ± 7 pg/mL), fibronectin (1139 ± 145
ng/mL) (all P < 0.05 vs. chronic progressive glomeru-
losclerosis), and PAI-1 (54 ± 8 ng/mL) (P = NS) (Fig. 4)
as measured by ELISA. Semiquantitative immunostain-
ing for TGF-b1, fibronectin, and PAI-1 is shown in Table
1 and was consistent with the ELISA readings.
At the glomerular level, the effects of FTY720 were
more moderate and did not reach statistical signifi-
cance (Fig. 5): Glomerular matrix score (chronic pro-
gressive glomerulosclerosis + FTY720 1.55 ± 0.10 and
chronic progressive glomerulosclerosis 2.10 ± 0.24), ex-
pression of TGF-b1 (chronic progressive glomeruloscle-
rosis + FTY720 103 ± 20 pg/mL and chronic progressive
glomerulosclerosis 149 ± 22 pg/mL), fibronectin (chronic
progressive glomerulosclerosis + FTY720 2655 ±
236 ng/mL and chronic progressive glomerulosclerosis
3586 ± 690 ng/mL), and PAI-1 (chronic progressive
glomerulosclerosis + FTY720 69 ± 9 ng/mL and chronic
progressive glomerulosclerosis 79 ± 5 ng/mL) as mea-
sured by ELISA. Comparable results were found for the
glomerular expression of these matrix proteins by im-
munostaining (Table 1).
Effects of FTY720 on plasma markers of renal function
As shown in Figure 6, chronic anti-thy 1 glomeru-
losclerosis was characterized by increases in plasma BUN
(chronic progressive glomerulosclerosis 73 ± 11 mg/dL
versus one-kidney control 45 ± 2 mg/dL, P < 0.01) and
creatinine levels (chronic progressive glomerulosclero-
sis 0.74 ± 0.05 mg/dL versus one-kidney control 0.62 ±
0.02 mg/dL, P < 0.05) and by decreased blood ery-
throcytes count (chronic progressive glomerulosclerosis
7.14 ± 0.24 versus one-kidney control 8.07 ± 0.40 ×
106/lL, P < 0.05). Treatment with FTY720 limited the
increase in BUN (51 ± 4 mg/dL, P < 0.05) and creatinine
(0.64 ± 0.02 mg/dL, P < 0.05) as well the decrease in
erythrocytes count (7.73 ± 0.15 × 106/lL, P = 0.11).
Together, these data document that the tubulointersti-
tial fibrosis went along with renal insufficiency in chronic
anti-thy 1 glomerulosclerosis, and that histologic benefits
from FTY720 were paralleled by improvement of plasma
markers of renal function.
Effects of FTY720 on renal cell infiltration
As shown in Figures 7 and 8, chronic progressive anti-
thy 1 glomerulosclerosis was characterized by a marked
glomerular and tubulointerstitial white cell infiltration
consisting of CD4–positive, CD8–positive (lymphocytes)
and ED1–positive (macrophages) cells. At the tubu-
lointerstitial level, CD4–positive cells increased 2.5-fold,
CD8–positive cells 3.8-fold and ED1–positive cells 3.9-
fold (Fig. 6) chronic progressive glomerulosclerosis vs.
one-kidney control, all P < 0.01), respectively. At the
glomerular level, corresponding increases were 6.1-fold,
3.2-fold, and 3.7-fold (Fig. 7, all P < 0.01), respectively.
In comparison to the untreated chronic anti-thy1
animals, treatment with FTY720 significantly pre-
vented tubulointerstitial infiltration with CD4 cells by
59% (chronic progressive glomerulosclerosis + FTY720
17.1 ± 2.8 vs. chronic progressive glomerulosclerosis
26.8 ± 2.7 cells/cortical section, P < 0.05) and CD8
cells by 83% (chronic progressive glomerulosclerosis
+ FTY720 8.6 ± 1.9 vs. chronic progressive glomeru-
losclerosis 23.4 ± 4.2 cells/cortical section, P < 0.01)
(Fig. 7). At the glomerular level, CD4 cells were low-
ered by 32% (chronic progressive glomerulosclerosis +
FTY720 1.2 ± 0.4 vs. chronic progressive glomeruloscle-
rosis 1.7 ± 0.4 cells/glomerular section, P = NS) and
CD8–positive cells by 82% (chronic progressive glomeru-
losclerosis + FTY720 0.4 ± 0.1 vs. chronic pro-
gressive glomerulosclerosis 1.1 ± 0.2 cells/glomerular
section, P < 0.01) (Fig. 8). As a matter of interest
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Table 1. Effects of FTY720 on tubulointerstitial and glomerular staining of transforming growth factor-b1 (TGF-b1), fibronectin, and
plasminogen activator inhibitor (PAI-1) 20 weeks after induction of chronic anti-thy 1 glomerulosclerosis
Tubulointerstitial Glomerular
Group TGF-b1 Fibronectin PAI-1 TGF-b1 Fibronectin PAI-1
Two-kidney control 0.08 ± 0.02 0.23 ± 0.08 0.28 ± 0.04 0.32 ± 0.08 0.20 ± 0.04 0.32 ± 0.08
One-kidney control 0.06 ± 0.02 0.29 ± 0.03 0.38 ± 0.06 0.29 ± 0.04 0.25 ± 0.04 0.36 ± 0.09
Chronic progressive glomerulosclerosis 1.82 ± 0.25 1.68 ± 0.28 1.54 ± 0.13 1.48 ± 0.13 2.00 ± 0.26 1.11 ± 0.06
Chronic progressive glomerulosclerosis + FTY720 0.83 ± 0.30a 0.84 ± 0.2a 0.85 ± 0.16a 1.06 ± 0.25 1.26 ± 0.30 1.02 ± 0.12
Nondiseased animals without (two-kidney control) and with uninephrectomy (one-kidney control) served as controls. Glomerular and tubulointerstitial staining
intensity was scored semiquantitatively using a 4-grade scale.
aP < 0.05 vs. chronic progressive glomerulosclerosis.
and an indication of its lymphocyte specificity, FTY720
did not significantly alter the macrophage infiltration of
the glomerulus (chronic progressive glomerulosclerosis
+ FTY720 1.3 ± 0.4 vs. chronic progressive glomeru-
losclerosis 1.2 ± 0.3 cells/glomerular section, respectively,
P = NS) (Fig. 8) and only moderately that of the tubu-
lointerstitium (chronic progressive glomerulosclerosis +
FTY720 18.8 ± 5.5 vs. chronic progressive glomeruloscle-
rosis 25.2 ± 5.3 cells/cortical section, P = 0.48 = NS)
(Fig. 7).
Taken in its entirety, the present experiment shows
that FTY720 selectively and effectively decreases blood
lymphocyte count and, subsequently, renal lymphocyte
infiltration in chronic anti-thy 1 glomerulosclerosis. The
selective lymphocyte inhibition achieved, in turn, pre-
vented the increase in proteinuria, lowered renal matrix
expansion, and improved plasma markers of renal func-
tion, thus limiting the progression from acute glomerular
to chronic tubulointerstitial fibrosis.
DISCUSSION
FTY720 is a novel, experimentally, and clinically ap-
plicable tool for the study of lymphocyte function, and
its role in future immunosuppressive treatment has just
begun to emerge [19, 20]. The compound was originally
derived from the ascomycete Isaria sinclairii product
myriocin (ISP-1), an “eternal youth” nostrum used in tra-
ditional Chinese medicine. Structurally, FTY720 belongs
to the group of sphingosines. Following endogenous phos-
phorylation by sphingosine kinases, FTY720 acts as an
agonist on four of the five G protein–coupled receptors
for sphingosine 1–phosphates [25, 28]. These receptors
are expressed on lymphocytes and endothel cells and are
thought to mediate the FTY720 effect on lymphocyte mi-
gration. As shown in several earlier studies [19, 20] and
as confirmed here in chronic anti-thy 1 glomerulosclero-
sis, FTY720 depletes peripheral blood from lymphocytes
in a unique and highly specific manner without affecting
granulocytes and monocytes. The molecular mechanism
underlying this effect is still incompletely understood,
but it is the consequence of a fast and long-lasting se-
lective redistribution of lymphocytes from the blood into
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Fig. 5. Effects of FTY720 on glomerular matrix accumulation (A) and
glomerular production of transforming growth factor-b1 (TGF-b1) (B),
fibronectin (C), and plasminogen activator inhibitor (PAI-1) (D) 20
weeks after induction of chronic anti-thy 1 glomerulosclerosis (cGS).
Matrix accumulation was scored histologically (grade 0 to 4). Matrix
protein production was determined in glomeruli harvested from indi-
vidual animals and cultured at a density of 2000/mL for 48 hours.
the spleen, peripheral lymph nodes, mesenteric lymph
tissue, and Peyer’s patches. It is currently being debated
whether this phenomenon is the result of increased hom-
ing (increased influx) or of increased trapping (decreased
efflux) of lymphocytes in these tissues, respectively [19].
In chronic anti-thy1 glomerulosclerosis, the highly sig-
nificant reduction of blood lymphocytes achieved by
FTY720 was followed by a marked decrease in the num-
ber of lymphocytes infiltrating the diseased kidneys, as
anticipated. As the major finding of this study, we ob-
served that the lymphocyte inhibition greatly limited
key features of progressive renal disease in this model,
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Fig. 6. Effects of FTY720 on markers of renal function 20 weeks af-
ter induction of chronic anti-thy 1 glomerulosclerosis (cGS). Shown
are plasma blood urea nitrogen (BUN) (A) and creatinine (B) lev-
els as markers of the excretory kidney function and blood erythrocyte
counts indicating the renal endocrine, erythropoetin-producing capac-
ity. Non-diseased animals without [two kidney control (2-K control)]
and with uninephrectomy [one kidney control (1-K control)] received
a phosphate-buffered saline (PBS) injection. ∗P < 0.05 and ∗∗P < 0.01
vs. chronic glomerulosclerosis.
including the continuous temporal increase of protein-
uria, the spread of glomerular TGF-b overexpression
and matrix expansion into the tubulointerstitial compart-
ment, and the decline in renal excretory and endocrine
function. Thus, this study points out that lymphocytes
play a key role in the advance of chronic anti-thy 1
glomerulosclerosis from an initially glomerular disease to
progressive tubulointerstitial fibrosis and functional in-
sufficiency. Interestingly, there was almost no increase
in systemic blood pressure. This is consistent with the
concept that chronic anti-thy 1 glomerulosclerosis rep-
resents a model of intrarenal progression not further
accelerated by extrarenally derived insults.
At the glomerular level, FTY720 lowered TGF-b over-
expression and matrix expansion as well, but the benefits
were more moderate than in the tubulointerstitium. At
first glance, this finding may indicate that the significance
of lymphocytes in glomerular fibrosis is less prominent
than in tubulointerstitial scar formation. However, we
think that this is rather related to the fact that FTY720
treatment was begun as late as 7 days after injection of
anti-thy 1 antibody, thus encountering an already estab-
lished glomerular disease. This view is supported by pre-
liminary studies showing that FTY720 is more effective in
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Fig. 7. Effects of FTY720 on tubulointerstitial cell infiltration. Shown
are CD4–positive (A) and CD8–positive (B) cells indicating lympho-
cytes and ED-1–positive cells (C) representing macrophages 20 weeks
after induction of chronic anti-thy 1 glomerulosclerosis (cGS). Nondis-
eased animals without [two-kidney control (2-K control)] and with
uninephrectomy [one-kidney control (1-K control)] served as controls.
Analysis was performed using specific murine primary antibody in con-
junction with a standard APAAP technique. Data are expressed as cells
per cortical section observed at ×200 magnification. ∗P < 0.05 and
∗∗P < 0.01 vs. chronic glomerulosclerosis.
reducing glomerular TGF-b overexpression and matrix
expansion when started as early as 24 hours after anti-
thy 1 antibody injection [abstract; Peters H, J Am Soc
Nephrol 13:133A, 2002].
The findings of this study go beyond previous inves-
tigations showing benefits of FTY720 in animal models
of organ transplantation and autoimmunity, in which a
key role of lymphocytes has already been established [19,
20]. Markedly prolonged graft survival through FTY720,
alone or in combination with cyclosporine, has recently
been documented in models of skin, heart, small bowel,
islets, liver, and kidney transplantation in rodents, dogs,
and nonhuman primates [19, 20]. The first human clin-
ical phase II trial has shown that FTY720 prevents
acute rejection in renal transplant patients on a baseline
immunosuppression with cyclosporine A and corticos-
teroids [19, 29]. With regard to autoimmunity, ben-
eficial effects of FTY720 have recently been shown
in experimental adjuvant- or collagen-induced arthritis,
autoimmune myocarditis, uveoretinitis, systemic lupus
erythematosus, autoimmune diabetes, thyreoiditis, and
acute and chronic-relapsing encephalitis [19, 20]. By
showing that lymphocytes contribute actively to the
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Fig. 8. Effects of FTY720 on glomerular cell infiltration. Shown are
CD4–positive (A) and CD8–positive (B) cells indicating lymphocytes
and ED1–positive cells (C) representing macrophages 20 weeks after in-
duction of chronic anti-thy 1 glomerulosclerosis (cGS). Nondiseased an-
imals without [two-kidney control (2-K control)] and with uninephrec-
tomy [one-kidney control (1-K control)] served as controls. Analysis
was performed using specific murine primary antibody in conjunction
with a standard APAAP technique. Data are expressed as cells per
glomerular cross-section. ∗∗P < 0.01 vs. chronic glomerulosclerosis.
tubulointerstitial fibrosis and subsequent impairment of
renal function in progressive anti-thy 1 glomeruloscle-
rosis, the present study is expanding the importance of
lymphocytes toward the rather unspecific accompanying
cell infiltration seen in chronic progressive renal disease.
Since many, if not all, progressive experimental and hu-
man nephropathies, such as in diabetes and hypertension,
share the feature of tubulointerstitial lymphocyte infiltra-
tion [1, 2, 10–12, 15], the findings for chronic anti-thy 1
glomerulosclerosis given here may be relevant for other
progressive nephropathies as well. This may probably
apply to both experimental and human chronic kidney
disease. Furthermore, since chronic diseases of other sys-
tems such as the heart, circulation, lungs, or liver also
show an apparently bystanding lymphocyte infiltration
[3–8], our findings might be of general importance to the
pathogenesis and future treatment of progressive organ
destruction and failure as well.
The benefits of FTY720 in chronic anti-thy 1 glomeru-
losclerosis are principally in line with early studies show-
ing structural and suggesting functional improvement of
rather less specific immunosuppression on the progres-
sion of immune and nonimmune models of progressive
renal disease [15]. These modes have included admin-
istration of fatty acid–deficient diets, x-ray irradiation,
and steroid therapy [15]. More recently, some studies
have shown that the presumably lymphocyte-targeting
drug mycophenolate mofetil (MMF) lowered protein-
uria, glomerular, vascular and tubulointerstitial fibrosis,
and preserved renal function in the rat model of 5/6
nephrectomy [30–32]. Although MMF was initially in-
troduced into transplantation medicine as a specific in-
hibitor of lymphocyte proliferation, it has become clear
that this drug has a number of additional actions. These
include antiproliferative effects on vascular smooth mus-
cle cells, mesangial cells, and renal fibroblasts in vivo
and in vitro [15], as well as inhibition of the produc-
tion of lymphocyte- and macrophage-derived cytokines
and growth factors such as platelet-derived growth fac-
tor (PDGF), interleukin (IL)-2, tumor necrosis factor-a
(TNF-a), and TGF-b . In contrast, FTY720 acts very se-
lectively on lymphocytes, and in the concentrations used,
has no effect of its own on cell proliferation [19], thus al-
lowing more conclusive interpretations as to the specific
role of lymphocytes in the progression of renal disease. It
may therefore well be that the recent studies using MMF
to study lymphocyte function might have overestimated
their actual role in chronic kidney diseases. This view is
supported by preliminary studies in chronic anti-thy 1
glomerulosclerosis, showing that the relative benefit from
MMF is greater than that of FTY720 [abstract; Kra¨mer,
J Am Soc Nephrol 13:542A, 2002]. In addition to greater
specificity toward lymphocyte function, another advan-
tage of FTY720 as an immunosuppressant may be related
to the finding that, unlike the currently used drugs, the
compound does not inhibit T-cell activation and prolifer-
ation. Thus, as recently shown in rodent models, FTY720
does not impair T and B memory in systemic viral infec-
tions [19, 33]. So far FTY720 has shown little side effects
being independent of its immunosuppressive actions [19,
20]. Of clinical importance is the experience that that
the first doses of FTY720 may leads to a marked reduc-
tion in hearth rate. This effect almost disappears with
further doses over the next days and has been related to
interactions with sphingosine 1 phosphate receptors ex-
pressed in the heart [19]. Furthermore, in very high doses
(5 mg/kg body weight) FTY720 has been found to reduce
body weight in Lewis rats through interference with renal
sodium handling [34].
While in transplantation and autoimmunity the impor-
tance of antigen specifically acting lymphocytes is well
established, it remains largely unclear why and how this
cell population influences the rather unspecific inflamma-
tion going along with progressive renal fibrosis and insuf-
ficiency [14, 15]. Several potential explanations should
be considered. First, although there is no convincing ev-
idence in nonimmune progressive renal nephropathies,
the lymphocytes may indeed autoreact with yet un-
defined renal antigenes. Such a case of unexpected
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autoreactivity has recently been shown in experimental
cardiac myoinfarction, in which autoreactive cytotoxic T
cells developed against heart myocytes and drove the dis-
ease toward heart failure [35]. Second, lymphocytes in-
teract closely with macrophages and thus may participate
indirectly in actions of the unspecific immune response
[14]. Third, activated lymphocytes are known to release
locally a number of inflammatory cytokines and fibrosis-
promoting growth factors, among them TGF-b , which
may directly amplify tubulointerstitial fibrosis [3, 14].
CONCLUSION
Using the selective lymphocyte inhibitor FTY720, the
present study shows that lymphocytes play an active role
in the progression of chronic anti-thy 1 glomeruloscle-
rosis toward tubulointerstitial fibrosis and insufficiency.
The relevance of this finding and the therapeutic poten-
tial of FTY720 for other progressive kidney diseases and
chronic organ failure in general warrant further investi-
gation.
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